上海众辰电子科技股份有限公司 累积投票制实施细则 上海众辰电子科技股份有限公司 第一章 总 则 第一条 为规范上海众辰电子科技股份有限公司（以下简称"公司"）董事、 监事的选举，保证公司所有股东充分行使权利，维护中小股东的合法权益，根据 《上市公司治理准则》《上海证券交易所股票上市规则》等法律、法规、规范性 文件及《上海众辰电子科技股份有限公司章程》（以下简称"公司章程"）的有 关规定，制定本细则。 第五条 公司依照公司章程规定的方式和程序确定董事候选人，确保选举的 公开、公平、公正。 第二条 公司股东会就选举两名以上董事进行表决时，实行累积投票制。 前款所称累积投票制是指股东会选举董事时，每一股份拥有与应选董事人数 相同的表决权，股东拥有的表决权可以集中使用。 第三条 本细则适用于公司董事（包括独立董事）的选举。由职工代表担任 的董事由公司职工代表大会以民主形式选举产生或更换，不适用于本实施细则的 相关规定。 第四条 公司通过累积投票制选举产生的董事，其任期不实施交错任期制， 即届中因缺额而补选的董事任期为本届余任期限，不跨届任职。 第二章 董事候选人的提名 第六条 董事候选人提名的方式为： （一）董事候选 ...

上海众辰电子科技股份有限公司 薪酬与考核委员会工作细则 上海众辰科技电子股份有限公司 董事会薪酬与考核委员会工作细则 第一章 总 则 第一条 为完善上海众辰电子科技股份有限公司（以下简称"公司"）法人 治理结构，制订科学、有效的薪酬管理制度，根据《上市公司治理准则》和《上 海众辰电子科技股份有限公司章程》（以下简称"《公司章程》"）及其他有关规定， 公司特设立薪酬与考核委员会，并制定本工作细则。 第二条 薪酬与考核委员会是设在董事会下的一个专门委员会。 第三条 薪酬与考核委员会必须遵守公司章程，在董事会授权的范围内独 立行使职权，并直接向董事会负责。 第四条 薪酬与考核委员会隶属于董事会，是董事会的专门参谋机构，对 董事会负责；薪酬与考核委员会也是公司的人力资源部有关重大问题的议事机 构。 第五条 薪酬与考核委员会应当保证公司有关薪酬与考核的重大政策在形 成决议前已得到了充分、专业、科学并合乎规范程序的论证。 第二章 薪酬与考核委员会的产生与组成 第六条 薪酬与考核委员会由三名委员组成，设主任委员一名。 第七条 薪酬与考核委员会委员由董事组成，其中独立董事委员不少于委 员会人数的二分之一。主任委员由独立董事担 ...

融券方面，当日融券卖出0.00万股，净卖出0.00万股。 来源：金融界 最近三个交易日，20日-22日，伟思医疗分别获融资买入0.36亿元、0.22亿元、0.15亿元。 8月22日，沪深两融数据显示，伟思医疗获融资买入额0.15亿元，居两市第1279位，当日融资偿还额0.22 亿元，净卖出649.73万元。 ...

Company Overview - Weisi Medical's closing price on August 22 was 54.72 CNY, with an increase of 1.11%, resulting in a rolling price-to-earnings (PE) ratio of 46.20 times and a total market capitalization of 5.241 billion CNY [1] - The company operates in the medical device sector, focusing on the research, production, and sales of medical devices, including magnetic stimulation, electrical stimulation, electrophysiology, consumables and accessories, and laser radiofrequency products [1] Financial Performance - For the first quarter of 2025, Weisi Medical reported a revenue of 95.9127 million CNY, representing a year-on-year increase of 9.40% [1] - The net profit for the same period was 33.2201 million CNY, showing a significant year-on-year growth of 52.71%, with a sales gross margin of 66.65% [1] Shareholder Information - As of March 31, 2025, Weisi Medical had 5,933 shareholders, an increase of 637 from the previous count, with an average holding value of 352,800 CNY and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical device industry is 56.95 times, with a median of 40.49 times, positioning Weisi Medical at the 85th rank within the industry [2] - The industry average market capitalization is 12.243 billion CNY, while Weisi Medical's market cap is 5.241 billion CNY [2]

Group 1 - The core point of the news is that Weisi Medical has seen significant financing activity, with a net buy of 2.96 million yuan on August 21, 2023, following recent trends in financing purchases [1] - Over the last three trading days from August 19 to August 21, Weisi Medical received financing purchases of 3.6 million yuan, 3.6 million yuan, and 2.2 million yuan respectively, indicating a consistent interest from investors [1] - On the short selling side, there were no shares sold or net sold on the same day, suggesting a lack of bearish sentiment towards the stock [1]

Company Overview - Weisi Medical's closing price on August 20 was 55.88 yuan, down 2.82%, with a rolling PE ratio of 47.18 times and a total market value of 5.352 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 59.32 times and a median of 39.97 times, placing Weisi Medical at the 83rd position in the industry ranking [1] Shareholder Information - As of March 31, 2025, Weisi Medical had 5,933 shareholders, an increase of 637 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Business Performance - In the first quarter of 2025, Weisi Medical reported revenue of 95.9127 million yuan, a year-on-year increase of 9.40%, and a net profit of 33.2201 million yuan, reflecting a year-on-year growth of 52.71%, with a gross profit margin of 66.65% [1] Industry Comparison - The PE ratios for other companies in the medical device sector range from 11.61 to 20.96, with Weisi Medical's PE ratio being higher than the industry average and median [2]

Core Insights - The brain-computer interface (BCI) industry is expected to accelerate its development due to proactive policy support from the government, with key technological breakthroughs anticipated by 2027 [1][2] - The global BCI market in the medical application sector is projected to reach $40 billion by 2030 and exceed $145 billion by 2040, indicating significant growth potential [1][5] Policy Support - The Ministry of Industry and Information Technology and six other departments issued guidelines to promote innovation in the BCI industry, aiming for breakthroughs in key technologies by 2027 and establishing advanced technical, industrial, and standard systems [2] - The guidelines also emphasize the application of BCI products across various sectors, including industrial manufacturing, healthcare, and consumer life, with plans to create 2 to 3 industrial development clusters [2] Payment Standardization - The National Healthcare Security Administration released a trial guideline for pricing projects related to neurological medical services, specifically establishing pricing for invasive BCI procedures [3] - Provinces such as Hubei, Zhejiang, and Jiangsu have set BCI medical pricing, addressing previous ambiguities in pricing standards and facilitating the adoption of BCI technologies in healthcare [3] Investment Activity - There has been a notable increase in investment activity within the BCI sector, with over 1,000 disclosed financing transactions and nearly 400 companies receiving investments totaling close to $10 billion as of April 2025 [4] - This influx of capital is expected to accelerate technological innovation and product iteration in the BCI field [4] Investment Recommendations - Companies such as Weisi Medical (688580.SH) are recommended for investment, with additional attention suggested for Xiangyu Medical (688626.SH), Mylande (688273.SH), and others [5]

Investment Rating - The report maintains an "Overweight" rating for the brain-computer interface (BCI) industry, indicating a positive outlook compared to the broader market [5][8]. Core Insights - The brain-computer interface industry is expected to experience significant development opportunities driven by technological innovations, policy support, and capital investments, with promising market prospects in healthcare and consumer sectors [2][5]. - The global market for brain-computer interfaces in medical applications is projected to reach $40 billion by 2030 and exceed $145 billion by 2040, according to McKinsey [5]. - The report recommends investing in Weisi Medical and suggests paying attention to companies like Xiangyu Medical, Mailande, Xinwei Medical, Aipeng Medical, Chengyitong, Meihao Medical, Chuangxin Medical, and Botuo Biological [5]. Summary by Sections Policy Support - The Ministry of Industry and Information Technology and six other departments issued an implementation opinion in July 2025, aiming for breakthroughs in key technologies by 2027 and establishing advanced technical, industrial, and standard systems [5][6]. - By 2030, the BCI industry is expected to significantly enhance its innovation capabilities and cultivate 2 to 3 globally influential leading enterprises [5][6]. Payment Standardization - In March 2025, the National Medical Insurance Administration released guidelines for pricing new BCI technologies, establishing clear cost references for hospitals and enhancing procurement confidence [5][6]. Investment Activity - The investment activity in the BCI sector has significantly increased, with over 1,000 disclosed financing transactions and nearly 400 companies receiving investments totaling close to $10 billion as of April 2025 [5][6]. Company Layout - The report outlines various companies in the BCI sector, including their establishment years, market strategies, and technological focuses, highlighting their contributions to the industry [7].

Company Overview - Weisi Medical closed at 57.5 yuan, up 3.08%, with a rolling PE ratio of 48.55, marking a new low in 385 days, and a total market capitalization of 5.507 billion yuan [1] - The company ranks 85th in the medical device industry, which has an average PE ratio of 59.49 and a median of 40.19 [1] Financial Performance - For Q1 2025, Weisi Medical reported revenue of 95.9127 million yuan, a year-on-year increase of 9.40%, and a net profit of 33.2201 million yuan, a year-on-year increase of 52.71%, with a gross profit margin of 66.65% [1] Institutional Holdings - As of Q1 2025, there is one institutional holder of Weisi Medical, which is a fund holding a total of 90,000 shares valued at 0.04 million yuan [1] Industry Comparison - The PE ratios for other companies in the medical device industry range from 11.65 to 20.67, with Weisi Medical's PE ratio being significantly higher than the industry average [2] - The industry average PE is 59.49, while the median is 40.19, indicating that Weisi Medical is positioned above the median in terms of valuation [2]

资金流向方面，今日主力资金净流入1201.23万元，占比成交额5.03%。其中，超大单净流入354.05万 元、占成交额1.48%，大单净流入847.18万元、占成交额3.55%，中单净流出流出282.67万元、占成交额 1.18%，小单净流出918.56万元、占成交额3.85%。 金融界消息 截至2025年8月19日收盘，伟思医疗（688580）报收于57.5元，上涨3.08%，换手率4.33%， 成交量4.15万手，成交金额2.39亿元。 通过天眼查大数据分析，南京伟思医疗科技股份有限公司共对外投资了11家企业，参与招投标项目1244 次，知识产权方面有商标信息173条，专利信息291条，此外企业还拥有行政许可167个。 来源：金融界 伟思医疗最新一期业绩显示，截至2025一季报，公司营业总收入9591.27万元、同比增长9.40%，归属净 利润3322.01万元，同比增长52.71%，扣非净利润3053.83万元，同比增长58.96%，流动比率7.579、速动 比率7.341、资产负债率8.47%。 天眼查商业履历信息显示，南京伟思医疗科技股份有限公司，成立于2001年，位于南京市，是一家以从 事医药制 ...